Pharmacology and Plaque - Cardiovascular Update

Computed tomographic angiography measures of coronary plaque in clinical trials: opportunities and considerations to accelerate drug translation

Frontiers in Cardiovascular Medicine

MARCH 4, 2024

The complex development of atherosclerosis manifests as intimal plaque which occurs in the presence or absence of traditional risk factors. Atherosclerotic coronary artery disease (CAD) is the causal pathological process driving most major adverse cardiovascular events (MACE) worldwide.

Plaque

Plaque Coronary Artery Disease Blood Pressure Cardiovascular Disease

What We Have Learned About Reducing Low-Density Lipoprotein Cholesterol and Coronary Plaques

JAMA Cardiology

SEPTEMBER 1, 2024

Pioneering work by Brown et al using a cumbersome manual technique known as quantitative coronary angiography (QCA) suggested that reduction in lesion severity with pharmacological treatment might be possible. However, the focus on lesion severity assumed that coronary thrombotic events most commonly occur at sites with severe stenoses.

Cholesterol

Cholesterol Plaque Pharmacology

Identification of M2 Macrophage-Related Key Genes in Advanced Atherosclerotic Plaques by Network Based Analysis

Journal of Cardiovascular Pharmacology

JANUARY 8, 2024

Atherosclerotic plaque accounts for major adverse cardiovascular events due to its vulnerability. The M1 and M2 macrophages are implicated in progression and regression of plaque, respectively. However, the therapeutic targets related M2 macrophages still remain largely elusive. or 0.001), respectively. All rights reserved.

Plaque

Plaque Article

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects

Circulation

FEBRUARY 9, 2025

Lp(a) can enter the vessel wall, leading to the accumulation of oxidized phospholipids in the arterial intima, which are crucial for initiating plaque inflammation and triggering vascular disease progression.

Pharmacology

Pharmacology Cardiovascular Disease Plaque Risk Factors

Atherosclerotic Plaque Erosion: Mechanisms, Clinical Implications, and potential therapeutic Strategies – a review

Journal of Cardiovascular Pharmacology

FEBRUARY 28, 2024

Atherosclerosis is an insidious and progressive inflammatory disease characterized by the formation of lipid-laden plaques within the intima of arterial walls with potentially devastating consequences. However, despite a heterogenous substrate underlying coronary thrombosis, treatment remains identical.

Plaque

Plaque Thrombosis Atherosclerosis Article

Association between the neutrophil-to-lymphocyte ratio and in-stent neoatherosclerosis and plaque vulnerability: An optical coherence tomography study

Journal of Cardiovascular Pharmacology

OCTOBER 9, 2024

Our study showed that an increased NLR was associated with ISNA and in-stent plaque fragility in patients with ISR following DES implantation. Our study showed that an increased NLR was associated with ISNA and in-stent plaque fragility in patients with ISR following DES implantation. Copyright © 2024 The Author(s).

Stents

Stents Stent Plaque Article

METTL4-Mediated Mitochondrial DNA N6-Methyldeoxyadenosine Promoting Macrophage Inflammation and Atherosclerosis

Circulation

DECEMBER 17, 2024

Through various experimental techniques, such as gene manipulation, pharmacological inhibition, and proteolysis targeting chimera, this study demonstrated that mtDNA 6mA and its specific enzyme METTL4 hold potential as therapeutic targets for atherosclerosis. Natural compound libraries were screened to identify potent METTL4 antagonists.

Atherosclerosis

Atherosclerosis Transplant Plaque Pharmacology

American College of Cardiology ACC.24 Late-breaking Science and Guidelines Session Summary

DAIC

FEBRUARY 29, 2024

24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 Atrial Fibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24

Aortic valve

Aortic valve Myocardial Infarction Aortic Blood Pressure

Naturally Occurring Atherosclerosis Progression and In-Stent Restenosis: Exploring Histomorphological Associations Using Optical Coherence Tomography

Journal of Cardiovascular Pharmacology

NOVEMBER 26, 2023

A significantly higher proportion of patients in the ISR with non-target lesion progression (N-TLP) group exhibited lipid plaque formation compared to the ISR without N-TLP group (69.0% The mechanism of ISR was emamined through qualitative and quantitative analysis of OCT imaging. versus 39.8%, P < 0.001). versus 39.8%, P < 0.001).

Stents

Stents Stent Atherosclerosis Plaque

Preventive Percutaneous Coronary Intervention for High-Risk Coronary Plaques Reduces Cardiac Events

DAIC

APRIL 11, 2024

These new findings suggest that people with high-risk plaques that are likely to rupture could benefit from the procedure as a pre-emptive measure rather than waiting for a heart attack or other severe reduction in blood flow to occur. During PCI, an operator inserts a stent into a blocked artery through a catheter in the groin or arm.

Plaque

Plaque Heart Attack Heart attacks Coronary Artery Disease

7 Things You Can Do To Reduce Your Risk Even If You Already Have Heart Disease.

Dr. Paddy Barrett

APRIL 5, 2024

5 High intensity interval training induces beneficial effects on coronary atheromatous plaques – a randomized trial, European Journal of Preventive Cardiology , 2022;, zwac309, 6 FOURIER Steering Committee and Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.

Heart Disease

Heart Disease Coronary Artery Disease Heart Attack Heart attacks

Lowering Atherosclerotic Cardiovascular Disease Events by Treating Residual Inflammatory Risk

DAIC

JANUARY 23, 2024

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 7 Research has shown inflammation plays a significant role in the development of atherosclerosis and ASCVD,8-10 and even the formation of plaque.11 4 In the U.S. 2015.06.013 31.

Cardiovascular Disease

Cardiovascular Disease Heart Attack Heart attacks Coronary Artery Disease

New Guidelines on Peripheral Artery Disease Issued by American Heart Association, American College of Cardiology and Leading Medical Societies

DAIC

MAY 16, 2024

PAD is a serious, progressive cardiovascular disease primarily caused by a buildup of fatty plaque in the blood vessels, or atherosclerosis. This plaque narrows the blood vessels and reduces blood flow to the legs and feet, which may significantly impair physical function, walking performance and quality of life.

Peripheral Arterial Disease

Peripheral Arterial Disease Exercise Ischemia Quality of Life

Arrhythmia? Ischemia? Both? Electricity, drugs, lytics, cath lab? You decide.

Dr. Smith's ECG Blog

NOVEMBER 26, 2018

The axiom of "type 1 (ACS, plaque rupture) STEMIs are not tachycardic unless they are in cardiogenic shock" is not applicable outside of sinus rhythm. We discussed several pharmacologic and electrical options. We first gave adenosine 6mg.

Ischemia

Ischemia Atrial Flutter Arrhythmia Tachycardia

Computed tomographic angiography measures of coronary plaque in clinical trials: opportunities and considerations to accelerate drug translation

What We Have Learned About Reducing Low-Density Lipoprotein Cholesterol and Coronary Plaques

Identification of M2 Macrophage-Related Key Genes in Advanced Atherosclerotic Plaques by Network Based Analysis

Webinars

Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects

Atherosclerotic Plaque Erosion: Mechanisms, Clinical Implications, and potential therapeutic Strategies – a review

Association between the neutrophil-to-lymphocyte ratio and in-stent neoatherosclerosis and plaque vulnerability: An optical coherence tomography study

METTL4-Mediated Mitochondrial DNA N6-Methyldeoxyadenosine Promoting Macrophage Inflammation and Atherosclerosis

American College of Cardiology ACC.24 Late-breaking Science and Guidelines Session Summary

Naturally Occurring Atherosclerosis Progression and In-Stent Restenosis: Exploring Histomorphological Associations Using Optical Coherence Tomography

Preventive Percutaneous Coronary Intervention for High-Risk Coronary Plaques Reduces Cardiac Events

7 Things You Can Do To Reduce Your Risk Even If You Already Have Heart Disease.

Lowering Atherosclerotic Cardiovascular Disease Events by Treating Residual Inflammatory Risk

New Guidelines on Peripheral Artery Disease Issued by American Heart Association, American College of Cardiology and Leading Medical Societies

Arrhythmia? Ischemia? Both? Electricity, drugs, lytics, cath lab? You decide.

Stay Connected